RT Conference Proceedings
T1 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
A1 Pujade-Lauraine, E.
A1 Selle, F.
A1 Scambia, G.
A1 Asselain, B.
A1 Marme, F.
A1 Lindemann, K.
A1 Colombo, N.
A1 Madry, R.
A1 Glasspool, R. M.
A1 Dubot, C.
A1 Oaknin, A.
A1 Zamagni, C.
A1 Heitz, F.
A1 Gladieff, L.
A1 Rubio-Perez, M. J.
A1 Scollo, P.
A1 Blakeley, C.
A1 Shaw, B.
A1 Ray-Coquard, I. L.
A1 Redondo, A.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/25339
UL https://hdl.handle.net/10668/25339
LA en
DS RISalud
RD Apr 6, 2025